Drug Trial News

RSS

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of depression in patients taking vortioxetine, an investigational agent under review with the U.S. Food and Drug Administration for the treatment of major depressive disorder.

20 May 2013

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Shire plc, the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association 166th Annual Meeting in San Francisco, May 18-22.

20 May 2013

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented key pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria.

18 May 2013

Insero Health announces top-line Phase Ib trial results of INS001 in patients with drug-resistant epilepsy

Insero Health, Inc., a company developing natural compounds to address unmet medical needs in epilepsy and related neurological disorders, is today reporting top-line results from a Phase Ib trial of its lead compound INS001 in patients with drug-resistant epilepsy.

17 May 2013

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

Galapagos NV and AbbVie announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3.

17 May 2013

A*STAR, Cytos Biotechnology provide update on Phase 1 clinical trial of H1N1 influenza vaccine

Singapore's Agency for Science, Technology and Research and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1 influenza vaccine candidate based on Cytos' proprietary bacteriophage Qbeta virus-like particle technology.

17 May 2013

Cedars-Sinai launches new clinical trial to study effects of cabozantinib in prostate cancer patients

Researchers at Cedars-Sinai have launched a new clinical trial to investigate the effects of a cancer-fighting drug therapy that has shown favorable outcomes in patients with advanced metastatic prostate cancer.

17 May 2013

NW Bio starts Phase III clinical trial with DCVax-L for brain cancer at King's College Hospital in UK

Northwest Biotherapeutics, a biotechnology company developing DCVax-L personalized immune therapies for solid tumor cancers, today announced that its Phase III clinical trial with DCVax-L for brain cancer has been initiated at King's College Hospital in the UK.

17 May 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

Idelalisib phase 1 clinical trial shows positive results in patients with CLL

A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia, according to a study led in part by Dana-Farber Cancer Institute investigators.

16 May 2013

Soligenix starts first clinical study for development of SGX203 for pediatric Crohn's disease

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.

15 May 2013

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.

15 May 2013

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully human monoclonal antibody directed against the IL-6 receptor, which is delivered by subcutaneous injection every other week, have enrolled their first patients.

15 May 2013

India's DBT, Bharat Biotech announce positive Phase III clinical trial results of rotavirus vaccine

The Government of India's Department of Biotechnology and Bharat Biotech announced positive results from a Phase III clinical trial of a rotavirus vaccine developed and manufactured in India.

14 May 2013

Clinical study reveals that Kava could be an alternative treatment for GAD

A world-first completed clinical study by an Australian team has found Kava, a medicinal South Pacific plant, significantly reduced the symptoms of people suffering anxiety.

14 May 2013

UNM Cancer Center to participate in Phase 3 clinical trial of novel treatment for men with prostate cancer

The University of New Mexico Cancer Center is among a few select institutions nationwide participating in a Phase 3 clinical trial studying a novel treatment for men with newly diagnosed, localized prostate cancer.

13 May 2013

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Lexicon Pharmaceuticals, Inc. announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pioneer portion of the trial.

10 May 2013

Drug Trial News

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

Insero Health announces top-line Phase Ib trial results of INS001 in patients with drug-resistant epilepsy

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

A*STAR, Cytos Biotechnology provide update on Phase 1 clinical trial of H1N1 influenza vaccine

Cedars-Sinai launches new clinical trial to study effects of cabozantinib in prostate cancer patients

NW Bio starts Phase III clinical trial with DCVax-L for brain cancer at King's College Hospital in UK

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Idelalisib phase 1 clinical trial shows positive results in patients with CLL

Soligenix starts first clinical study for development of SGX203 for pediatric Crohn's disease

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

India's DBT, Bharat Biotech announce positive Phase III clinical trial results of rotavirus vaccine

Clinical study reveals that Kava could be an alternative treatment for GAD

UNM Cancer Center to participate in Phase 3 clinical trial of novel treatment for men with prostate cancer

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Headline results of Creabilis' CT327 Phase 2b trial in psoriasis patients announced

InSite Vision starts patient enrollment in confirmatory Phase 3 clinical trial of BromSite

Synageva BioPharma reports study results of sebelipase alfa in adults with late onset LAL Deficiency

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Latest News